This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

Watch Vera Hirsh on AE management and treatment discontinuation!

PFS (LUX-Lung 7 clinical data)
GIOTRIF® significantly improved PFS versus gefitinib1

LUX-Lung 7: PFS by independent review (coprimary endpoint)

  • 27% reduction in relative risk of disease progression versus gefitinib (HR=0.73; 95% CI, 0.57–0.95; P=0.017)1
  • Patients were twice as likely to be alive and progression-free at 2 years versus gefitinib1
  • PFS benefit consistent across subgroups, including EGFR mutation type1

ORR (LUX-Lung 7 clinical data)
GIOTRIF® significantly improved response rates versus gefitinib in patients with both del19 and L858R1

  • Improved ORR and disease control rates versus gefitinib (ORR: 70% vs 56%; P=0.0083)1
  • Longer duration of response versus gefitinib (10.1 vs 8.4 months, respectively)1

ORR=objective response rate; PFS=progression-free survival; TTF=time to treatment failure.

TTF (LUX-Lung 7 clinical data)
Patients remained on treatment with GIOTRIF® significantly longer than with gefitinib1

LUX-Lung 7: Time to treatment failure (coprimary endpoint)

LUX-Lung 7: Time to treatment failure (coprimary endpoint)

  • GIOTRIF® significantly extended TTF versus gefitinib1
  • TTF chosen to reflect real-world clinical practice and treatment guidelines; ~30% of patients continued on treatment with TKIs beyond radiological progression in the absence of clinical deterioration1
  • 27% significant reduction in relative risk of treatment failure versus gefitinib (P=0.0073)1

CI=confidence interval; EGFR=epidermal growth factor receptor; HR=hazard ratio; PFS=progression-free survival.

Watch Dr. Riyaz Shah and Dr. Jason Lester discuss LUX-Lung 7 subgroup analyses, and the consistent PFS benefit across subgroups with GIOTRIF® 

Here Prof. James Yang, Prof. Keunchil Park and Dr. Terufumi Kato review the LUX-Lung 7 clinical trial results

You may be interested in: 

Is this information compelling to you?

Request contact
from Boehringer Ingelheim

References

  1. Park K et al. Lancet Oncol. 2016;17(5):577-589.
  2. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.
  3. Wu YL et al. Lancet Oncol. 2014;15(2):213-222.
  4. Soria JC et al. Lancet Oncol. 2015;16(8):897-907.
  5. Solca F et al. J Pharmacol Exp Ther. 2012;343(2):342-350.
  1. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.

  2. Wu YL et al. Lancet Oncol. 2014;15(2):213-222.

  3. Yang JC et al. Lancet Oncol. 2015;16(2):141-151.

  4. Park K et al. Lancet Oncol. 2016;17(5):577-589.

  5. Soria JC et al. Lancet Oncol. 2015;16(8):897-907.

  6. Solca F et al. J Pharmacol Exp Ther. 2012;343(2):342-350.

  7. Yang JC et al. J Clin Oncol. 2013;31(27):3342-3350.

  8. Hirsch V et al. Poster #369 presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; 3-7 June 2016.

  9. Yang JCH et al. Ann Oncol. 2016;27(11):2103-2110.

  10. Schuler M et al. J Thorac Oncol. 2016;11(3):380-390.

  11. Paz-Arez L et al. Ann Oncol. 2017; doi: 10.1093/annonc/mdw611.

  12. GIOTRIF® (afatinib) Summary of Product Characteristics, 2016.

Report an adverse event

If you wish to report an adverse event (AE) after treatment with one of our products, please select your site from the link below. This will allow reporting of AEs in line with the reporting procedure effective in your country for reporting.

Boehringer Ingelheim local websites
Back to top